Literature DB >> 9574724

Use of voriconazole in treatment of Scedosporium apiospermum infection: case report.

C Girmenia1, G Luzi, M Monaco, P Martino.   

Abstract

We report a case of disseminated Scedosporium apiospermum infection in a neutropenic patient with acute myeloid leukemia. Due to progression of the mycosis after 7 days of amphotericin B lipid complex therapy and to high susceptibility of the mold to voriconazole in vitro, the patient was treated with intravenous voriconazole. After a few days of therapy, fever disappeared and skin lesions improved. However, the patient died after 1 month due to intestinal bleeding. Despite a negative outcome, this case seems to indicate a promising role for voriconazole in the treatment of S. apiospermum infections.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9574724      PMCID: PMC104847          DOI: 10.1128/JCM.36.5.1436-1438.1998

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  19 in total

1.  In vitro evaluation of voriconazole against some clinically important fungi.

Authors:  M R McGinnis; L Pasarell; D A Sutton; A W Fothergill; C R Cooper; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Successful treatment of Scedosporium apiospermum suppurative arthritis with itraconazole.

Authors:  J P Piper; J Golden; D Brown; J Broestler
Journal:  Pediatr Infect Dis J       Date:  1990-09       Impact factor: 2.129

3.  A case of disseminated Scedosporium apiospermum infection after bone marrow transplantation.

Authors:  D Guyotat; M A Piens; R Bouvier; D Fiere
Journal:  Mykosen       Date:  1987-04

4.  Successful treatment of pneumonia due to Scedosporium apiospermum with itraconazole: case report.

Authors:  J Nomdedéu; S Brunet; R Martino; A Altés; V Ausina; A Domingo-Albós
Journal:  Clin Infect Dis       Date:  1993-05       Impact factor: 9.079

5.  Successful treatment of simultaneous pulmonary Pseudallescheria boydii and Aspergillus terreus infection with oral itraconazole.

Authors:  S L Goldberg; D J Geha; W F Marshall; D J Inwards; H C Hoagland
Journal:  Clin Infect Dis       Date:  1993-06       Impact factor: 9.079

6.  Pseudallescheria boydii infection after bone marrow transplantation.

Authors:  C H Gumbart
Journal:  Ann Intern Med       Date:  1983-08       Impact factor: 25.391

7.  Pseudallescheria boydii brain abscess: association with near-drowning and efficacy of high-dose, prolonged miconazole therapy in patients with multiple abscesses.

Authors:  D L Dworzack; R B Clark; W J Borkowski; D L Smith; M Dykstra; M P Pugsley; E A Horowitz; T L Connolly; D L McKinney; M K Hostetler
Journal:  Medicine (Baltimore)       Date:  1989-07       Impact factor: 1.889

Review 8.  Clinical significance of Pseudallescheria boydii: a review of 10 years' experience.

Authors:  L B Travis; G D Roberts; W R Wilson
Journal:  Mayo Clin Proc       Date:  1985-08       Impact factor: 7.616

9.  Visceral fungal infections due to Petriellidium boydii (allescheria boydii). In vitro drug sensitivity studies.

Authors:  L I Lutwick; J N Galgiani; R H Johnson; D A Stevens
Journal:  Am J Med       Date:  1976-11       Impact factor: 4.965

10.  Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

Authors:  E Estey; P Thall; M Andreeff; M Beran; H Kantarjian; S O'Brien; S Escudier; L E Robertson; C Koller; S Kornblau
Journal:  J Clin Oncol       Date:  1994-04       Impact factor: 44.544

View more
  26 in total

1.  Cutaneous Scedosporium apiospermum infection in an immunocompromised patient.

Authors:  C P Bower; J D Oxley; C K Campbell; C B Archer
Journal:  J Clin Pathol       Date:  1999-11       Impact factor: 3.411

Review 2.  Pulmonary scedosporiosis mimicking aspergilloma in an immunocompetent host: a case report and review of the literature.

Authors:  Fasih Ur Rahman; Muhammad Irfan; Naima Fasih; Kauser Jabeen; Hasanat Sharif
Journal:  Infection       Date:  2015-09-09       Impact factor: 3.553

3.  In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates.

Authors:  Joseph Meletiadis; Jacques F G M Meis; Johan W Mouton; Juan Luis Rodriquez-Tudela; J Peter Donnelly; Paul E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma.

Authors:  S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  In vitro synergistic interaction between amphotericin B and micafungin against Scedosporium spp.

Authors:  Clara Yustes; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  In vitro activities of four novel triazoles against Scedosporium spp.

Authors:  A J Carrillo; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

8.  Correlation between in vitro susceptibility of Scedosporium apiospermum to voriconazole and in vivo outcome of scedosporiosis in guinea pigs.

Authors:  Javier Capilla; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  [Foot injury as a rare cause of scendosporiosis with fetal outcome].

Authors:  P H Pennekamp; O Diedrich; H Zhou; C N Kraft
Journal:  Unfallchirurg       Date:  2003-10       Impact factor: 1.000

Review 10.  Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.

Authors:  Helen W Boucher; Andreas H Groll; Christine C Chiou; Thomas J Walsh
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.